| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $209,143 ) |
| | 2024 | 2024 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6, EDMUND CRESCENT | LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 4 | NIH | 5/22/2024 | $1 |
| | 2024 | 2024 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6, EDMUND CRESCENT | LAGOS | | | | NGA | K43TW012648 | Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa | 000 | 2 | NIH | 5/6/2024 | $65,447 |
| | 2024 | 2024 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6, EDMUND CRESCENT | LAGOS | | | | NGA | K43TW012648 | Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa | 002 | 2 | NIH | 9/17/2024 | $45,000 |
| | 2024 | 2024 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6, EDMUND CRESCENT | LAGOS | | | | NGA | K43TW012648 | Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa | 002 | 2 | NIH | 9/17/2024 | $3,488 |
| | 2024 | 2024 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6, EDMUND CRESCENT | LAGOS | | | | NGA | K43TW012648 | Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa | 001 | 2 | NIH | 9/16/2024 | $0 |
| | 2024 | 2024 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6, EDMUND CRESCENT | LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 4 | NIH | 5/22/2024 | $95,207 |
|
| Issue Date FY: 2023 ( Subtotal = $159,405 ) |
| | 2023 | 2023 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW012648 | Use of Pharmacoepidemiology to Understand Predictors and Impact of Low-level Viremia in Persons with HIV in West Africa | 000 | 1 | NIH | 7/17/2023 | $65,433 |
| | 2023 | 2023 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 3 | NIH | 6/1/2023 | $1 |
| | 2023 | 2023 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 3 | NIH | 6/1/2023 | $93,971 |
|
| Issue Date FY: 2022 ( Subtotal = $91,601 ) |
| | 2022 | 2022 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 002 | 2 | NIH | 4/15/2022 | $91,600 |
| | 2022 | 2022 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 002 | 2 | NIH | 4/15/2022 | $1 |
| | 2022 | 2021 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 001 | 1 | NIH | 11/30/2021 | $0 |
| | 2022 | 2021 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 001 | 1 | NIH | 11/30/2021 | $0 |
| | 2022 | 2021 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 1 | NIH | 11/19/2021 | $0 |
| | 2022 | 2021 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 1 | NIH | 11/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $93,106 ) |
| | 2021 | 2021 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 1 | NIH | 9/17/2021 | $93,105 |
| | 2021 | 2021 | NIGERIAN INSTITUTE OF MEDICAL RESEARCH | 6 EDMUND CRESCENT | YABA, LAGOS | | | | NGA | K43TW011926 | Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians | 000 | 1 | NIH | 9/17/2021 | $1 |
|
| Issue Date FY: 2020 ( Subtotal = -$48 ) |
| | 2020 | 2015 | Nigerian Institute Of Medical Research | 6 Edmund Crescent | Yaba, Lagos | province | postal_code | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 08 | 2 | CDC | 9/18/2020 | -$48 |
| | 2020 | 2014 | Nigerian Institute Of Medical Research | 6 Edmund Crescent | Yaba, Lagos | province | postal_code | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 08 | 2 | CDC | 9/18/2020 | $0 |
| | 2020 | 2013 | Nigerian Institute Of Medical Research | 6 Edmund Crescent | Yaba, Lagos | province | postal_code | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 08 | 2 | CDC | 9/18/2020 | $0 |
| | 2020 | 2013 | Nigerian Institute Of Medical Research | 6 Edmund Crescent | Yaba, Lagos | province | postal_code | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 08 | 2 | CDC | 9/18/2020 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $0 ) |
| | 2016 | 2015 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 002 | 2 | CDC | 3/15/2016 | $0 |
| | 2016 | 2014 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 001 | 2 | CDC | 3/15/2016 | $0 |
| | 2016 | 2014 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 000 | 2 | CDC | 10/22/2015 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $494,864 ) |
| | 2015 | 2015 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | Lagos | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 001 | 2 | CDC | 3/3/2015 | $494,864 |
| | 2015 | 2015 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 002 | 2 | CDC | 4/24/2015 | $0 |
| | 2015 | 2014 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 003 | 2 | CDC | 4/24/2015 | $0 |
| | 2015 | 2014 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 000 | 2 | CDC | 12/3/2014 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $5,000 ) |
| | 2014 | 2014 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 002 | 2 | CDC | 12/3/2014 | $0 |
| | 2014 | 2014 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | Lagos | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 001 | 2 | CDC | 7/25/2014 | $5,000 |
| | 2014 | 2013 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 000 | 1 | CDC | 6/24/2014 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $497,957 ) |
| | 2013 | 2013 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 001 | 1 | CDC | 8/22/2013 | $0 |
| | 2013 | 2013 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | Lagos | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 000 | 1 | CDC | 8/15/2013 | $497,957 |
| | 2013 | 2013 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 002 | 1 | CDC | 9/18/2013 | $0 |
| | 2013 | 2013 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 003 | 1 | CDC | 9/19/2013 | -$497,957 |
| | 2013 | 2013 | Nigerian Institute of Medical Research (NIMR) | 6 Edmond Cresent | LAGOS | | | | NGA | U01GH000770 | HIV Drug Resistance: Implications for Optimizing Antiretroviral Therapy | 004 | 1 | CDC | 9/20/2013 | $497,957 |
|
|
Friday, April 25, 2025
4/25/2025
